CXCR4 and neoplasm: In contrast to OV-Fc, and aligned with the ability of the virally-delivered CXCR4 antagonist to reduce the immunosuppressive network in the TME14, 17, 18, secretion of CXCR4-A into the perivascular tumor areas from virally infected tumor cells created milder inflammation that modulated the level and quality of myeloid cell responses associated with the generation of functional TCRTAG cells.